Edition:
United Kingdom

Sellas Life Sciences Group Inc (SLS.OQ)

SLS.OQ on NASDAQ Stock Exchange Capital Market

1.62USD
8:37pm BST
Change (% chg)

$-0.08 (-4.71%)
Prev Close
$1.70
Open
$1.68
Day's High
$1.69
Day's Low
$1.62
Volume
46,696
Avg. Vol
111,578
52-wk High
$17.70
52-wk Low
$1.60

Chart for

About

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunothera... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $15.70
Shares Outstanding(Mil.): 38.41
Dividend: --
Yield (%): --

Financials

  SLS.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -0.86 -- --
ROI: -59.58 15.07 14.61
ROE: -79.40 16.60 16.34

BRIEF-Sellas Life Sciences Files For Offering Of Up To $30 Mln

* SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING Source text: (https://bit.ly/2klt2uI) Further company coverage:

23 May 2018

BRIEF-Sellas Life Sciences Receives FDA Orphan Drug Designation For Galinpepimut-S For Treatment Of Multiple Myeloma

* SELLAS LIFE SCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GALINPEPIMUT-S (GPS) FOR TREATMENT OF MULTIPLE MYELOMA (MM) Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Sellas Life Sciences Ceases Gregory Torre's Employment As Chief Regulatory Officer

* SELLAS LIFE SCIENCES GROUP- ON APRIL 19, CO AND GREGORY TORRE, AGREED THAT HIS EMPLOYMENT AS CHIEF REGULATORY OFFICER WOULD CEASE - SEC FILING

24 Apr 2018

BRIEF-Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer

* SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER

20 Apr 2018

BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin

* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS

02 Apr 2018

BRIEF-Sellas Life Sciences Announces $10.7 Mln Private Placement

* SELLAS LIFE SCIENCES ANNOUNCES $10,700,000 PRIVATE PLACEMENT

07 Mar 2018

Competitors

Earnings vs. Estimates